Clinical Efficacy and Safety of Compound Methyl Salicylate Liniment

• Status: Completed
• Trial end date: 2009-06-12
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial program was established according to the ethical principles of the Helsinki declaration and the GCP guiding principle, and a randomized grouping method was used to evaluate the efficacy and safety of Compound Methyl Salicylate Liniment in the treatment of acute and chronic soft tissue pain with a positive control drug, named Diclofenac Sodium Liniment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University People's Hospital
• Treatments: Diclofenac; Methyl salicylate; Salicylates; Salicylic Acid

Criteria

Inclusion Criteria:

• Patients with various causes of acute and chronic soft tissue

• Local symptoms and signs include pain, swelling, bruising, tenderness, joint dysfunction; X-ray showed no fracture, dislocation, bone tumors and bone metabolism and open injury.

Exclusion Criteria:

• Patients who do not belong to the scope of drug use

• Muscle, tendon, ligament and other soft tissue have broken completely

• Accompanied by skin damage or fracture, joint dislocation, bone tumor and metabolic bone disease local tissue damage

• Use of other drugs or therapies for the treatment of acute and chronic soft tissue pain after trauma

• Difficult to evaluate the effectiveness and safety of new drugs

• Severe hypertension, severe heart and lung dysfunction, severe arrhythmia, liver, kidney, hematopoietic system and other serious primary diseases, mental patients

• Pregnant women, lactating women

• Allergic constitution and allergic to the known components of the drug

• Participated in other clinical trials in the past month

• Use similar analgesics within a week

• Other researchers considered inappropriate patients to participate in the trial